Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part Phase IIa Randomised, Double-blind, Placebo-controlled, Dose-ranging, Multi-centre Study to Assess Efficacy and Safety of Inhaled AZD1402 Administered as a Dry Powder for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT04643158 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04643158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04643158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part Phase IIa Randomised, Double-blind, Placebo-controlled, Dose-ranging, Multi-centre Study to Assess Efficacy and Safety of Inhaled AZD1402 Administered as a Dry Powder for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
March 12, 2021
Completion date
July 20, 2023
Enrollment
72 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

asthma